GeneralBearishBlockonomi · 3h ago6/10
📰
Zealand Pharma (ZEAL) Plummets 25% on Survodutide Tolerability Concerns
Zealand Pharma's stock declined 25% following trial results showing that survodutide, an obesity treatment candidate, caused significant tolerability issues with 25% of patients discontinuing due to gastrointestinal side effects. Despite demonstrating strong weight loss efficacy, the high dropout rate raises questions about the drug's commercial viability and market positioning against competing obesity treatments.